<u>WHAT IS CLAIMED IS:</u>

1.   A method for determining whether a subject has or is predisposed for a mental disorder, the method comprising the steps of:

(i) obtaining a biological sample from a subject;

(ii) contacting the sample with a reagent that selectively associates with a polynucleotide or polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to a nucleotide sequence of SEQ ID NO:1 or 3; and

(iii) detecting the level of reagent that selectively associates with the sample, thereby determining whether the subject has or is predisposed for a mental disorder.

2.   The method of claim 1, wherein the reagent is an antibody.

3.   The method of claim 1, wherein the reagent is a nucleic acid.

4.   The method of claim 1, wherein the reagent associates with a polynucleotide.

5.   The method of claim 1, wherein the regent associates with a polypeptide.

6.   The method of claim 1, wherein the level of reagent that associates with the sample is different from a level associated with humans without a mental disorder.

7.   The method of claim 1, wherein the biological sample is obtained from amniotic fluid.

8.   The method of claim 1, wherein the mental disorder is a mood disorder or psychosis.

9.   The method of claim 7, wherein the mood disorder is selected from the group consisting of bipolar disorder and major depression.

10.   The method of claim 8, wherein the psychosis is schizophrenia.

11.   The method of claim 1, wherein the polynucleotide comprises a nucleotide sequence of SEQ ID NO:1 or 3.

1   12.   The method of claim 1, wherein the polypeptide comprises an amino

2   acid sequence of SEQ ID NO:2 or 4.

1   13.   A method of identifying a compound for treatment of a mental

2   disorder, the method comprising the steps of:

3   (i) contacting the compound with a polypeptide, the polypeptide encoded by a

4   polynucleotide that hybridizes under stringent conditions to a nucleic acid sequence

5   comprising a nucleotide sequence of SEQ ID NO:1 or 3; and

6   (ii) determining the functional effect of the compound upon the polypeptide,

7   thereby identifying a compound for treatment of a mental disorder.

1   14.   The method of claim 13, wherein the contacting step is performed *in*

2   *vitro.*

1   15.   The method of claim 13, wherein the polypeptide is expressed in a cell

2   and the cell is contacted with the compound.

1   16.   The method of claim 13, wherein the mental disorder is a mood

2   disorder or psychosis.

1   17.   The method of claim 16, wherein the mood disorder is selected from

2   the group consisting of bipolar disorder and major depression.

1   18.   The method of claim 16, wherein the psychosis is schizophrenia.

1   19.   The method of claim 18, further comprising administering the

2   compound to an animal and determining the effect on the animal.

1   20.   The method of claim 19, wherein the determining step comprises

2   testing the animal's mental function.

1   21.   The method of claim13, wherein the polypnucleotide comprising a

2   nucleotide sequence of SEQ ID NO:1or 3.

1   22.   The method of claim 13, wherein the polypeptide comprises an amino

2   acid sequence of SEQ ID NO:2 or 4.

1   23.   A method of identifying a compound for treatment of a mental disorder

2   in a subject, the method comprising the steps of:

3   (i) contacting the compound to a cell, the cell comprising a polynucleotide that

4   hybridizes under stringent conditions to a nucleotide sequence of SEQ ID NO:1 or 3; and

5   (ii) selecting a compound that modulates expression of the polynucleotide,

6   thereby identifying a compound for treatment of a mental disorder.

1   24.   The method of claim 23, wherein the expression of the polynucleotide

2   is enhanced.

1   25.   The method of claim 23, wherein the expression of the polynucleotide

2   is decreased.

1   26.   The method of claim 23, further comprising administering the

2   compound to an animal and determining the effect on the animal.

1   27.   The method of claim 26, wherein the determining step comprises

2   testing the animal's mental function.

1   28.   The method of claim 23, wherein the mental disorder is a mood

2   disorder or psychosis.

1   29.   The method of claim 28, wherein the mood disorder is selected from

2   the group consisting of bipolar disorder and major depression.

1   30.   The method of claim 28, wherein the psychosis is schizophrenia.

1   31.   The method of claim 23, wherein the polynucleotide comprises a

2   nucleotide sequence of SEQ ID NO:1 or 3.

1   32.   A method of treating a mental disorder in a subject, the method

2   comprising the step of administering to the subject a therapeutically effective amount of a

3   compound identified using the method of claim 13 or claim 23.

1   33.   The method of claim 32, wherein the mental disorder is a mood

2   disorder or psychosis.

1   34.   The method of claim 33, wherein the mood disorder is selected from
2   the group consisting of bipolar disorder and major depression.

1   35.   The method of claim 33, wherein the psychosis is schizophrenia.

1   36.   The method of claim 32, wherein the compound is a nucleic acid.

1   37.   The method of claim 36, wherein the nucleic acid hybridizes under
2   stringent conditions to a nucleic acid comprising a nucleotide sequence of SEQ ID NO:1 or 3.

1   38.   The method of claim 32, wherein the compound is identified using the
2   method of claim 14 and the polynucleotide comprises a nucleotide sequence of SEQ ID NO:1
3   or 3.

1   39.   The method of claim 32, wherein the compound is identified using the
2   method of claim 14 and the polypeptide comprises an amino acid sequence of SEQ ID NO:2
3   or 4.

1   40.   The method of claim 32, wherein the compound is identified using the
2   method of claim 24 and the polynucleotide comprises a nucleotide sequence of SEQ ID NO:
3   1 or 3.

1   41.   A method of treating mental illness in a subject, the method
2   comprising the step of administering to the subject a therapeutically effective amount of a
3   polypeptide, the polypeptide encoded by a polynucleotide that hybridizes under stringent
4   conditions to a nucleotide sequence of SEQ ID NO:1 or 3.

1   42.   The method of claim 41, wherein the polynucleotide comprises a
2   nucleotide sequence of SEQ ID NO:1 or 3.

1   43.   The method of claim 41, wherein the mental illness is a mood disorder
2   or psychosis.

1   44.   The method of claim 43, wherein the mood disorder is selected from
2   the group consisting of bipolar disorder and major depression.

1   45.   The method of claim 43, wherein the psychosis is schizophrenia.

1   46.   A method of treating mental illness in a subject, the method
2   comprising the step of administering to the subject a therapeutically effective amount of a
3   nucleic acid, wherein the nucleic acid hybridizes under stringent conditions to a nucleotide
4   sequence of SEQ ID NO:1 or 3.

1   47.   The method of claim 46, wherein the mental illness is a mood disorder
2   or psychosis.

1   48.   The method of claim 47, wherein the mood disorder is selected from
2   the group consisting of bipolar disorder and major depression.

1   49.   The method of claim 47, wherein the psychosis is schizophrenia.

1   50.   The method of claim 46, wherein the nucleic acid comprises a
2   complementary sequence to the nucleotide sequence of SEQ ID NO:1 or 3.